These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 9395755)
1. Interferon therapy. Williams CN Can J Gastroenterol; 1997 Oct; 11(7):563-4. PubMed ID: 9395755 [No Abstract] [Full Text] [Related]
2. [The drug of first choice: interferon. Clinical pharmacological principles]. Del Vecchio S; Dianzani F Minerva Gastroenterol Dietol; 1995 Mar; 41(1):81-7. PubMed ID: 7542487 [No Abstract] [Full Text] [Related]
3. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Russo MW; Goldsweig CD; Jacobson IM; Brown RS Am J Gastroenterol; 2003 Jul; 98(7):1610-5. PubMed ID: 12873587 [TBL] [Abstract][Full Text] [Related]
7. [Interferon and plasma lipids]. García-Escaño MD; Andrade RJ; González-Santos P Med Clin (Barc); 2000 Jan; 114(2):74-6. PubMed ID: 10702954 [No Abstract] [Full Text] [Related]
8. Interferon and its therapeutic potential. Ho M Med J Aust; 1979 Jul; 2(1):11-2. PubMed ID: 228169 [No Abstract] [Full Text] [Related]
9. Prospective study of interferon therapy for compensated cirrhotic patients with chronic hepatitis C by monitoring serum hepatitis C RNA. Shiratori Y; Yokosuka O; Nakata R; Ihori M; Hirota K; Katamoto T; Unuma T; Okano K; Ikeda Y; Hirano M; Kawase T; Takano S; Matsumoto K; Ohashi Y; Omata M Hepatology; 1999 May; 29(5):1573-80. PubMed ID: 10216145 [TBL] [Abstract][Full Text] [Related]
10. Outcome of treatment with pegylated interferon and ribavirin in heart transplant recipients with chronic hepatitis C. Durante-Mangoni E; Ragone E; Pinto D; Iossa D; Covino FE; Maiello C; Utili R Transplant Proc; 2011; 43(1):299-303. PubMed ID: 21335209 [TBL] [Abstract][Full Text] [Related]
11. Progress in the development and use of antiviral drugs and interferon. Report of a WHO Scientific Group. World Health Organ Tech Rep Ser; 1987; 754():1-28. PubMed ID: 2444034 [No Abstract] [Full Text] [Related]
12. [The interferon system with special reference to gamma-interferons]. Kirchner H Dtsch Med Wochenschr; 1986 Jan; 111(2):64-70. PubMed ID: 2416525 [No Abstract] [Full Text] [Related]
13. Pharmacotherapy of hepatitis B infection: a brief review. Quan DJ Nephrol Nurs J; 2008; 35(5):507-10, 534. PubMed ID: 18856082 [TBL] [Abstract][Full Text] [Related]
14. Why do so many cancer patients fail to respond to interferon therapy? Einhorn S; Grander D J Interferon Cytokine Res; 1996 Apr; 16(4):275-81. PubMed ID: 9162520 [TBL] [Abstract][Full Text] [Related]
16. Novel interferons for treatment of hepatitis C virus. Clark V; Nelson DR Clin Liver Dis; 2009 Aug; 13(3):351-63. PubMed ID: 19628153 [TBL] [Abstract][Full Text] [Related]
17. [Neurologic side effects of interferon therapy]. Kohira I Ryoikibetsu Shokogun Shirizu; 1999; (27 Pt 2):610-3. PubMed ID: 10434732 [No Abstract] [Full Text] [Related]
18. Side effects. Safety and effectiveness of interferon and ribavirin in HIV+ people co-infected with hepatitis C virus. TreatmentUpdate; 2001; 12(8):4-5. PubMed ID: 12132439 [No Abstract] [Full Text] [Related]
19. Interferons and interferon inducers: development of clinical usefulness and therapeutic promise. Pollard RB Drugs; 1982; 23(1-2):37-55. PubMed ID: 6173188 [No Abstract] [Full Text] [Related]
20. Potential mechanisms of interferon neurotoxicity. Bender CM; Monti EJ; Kerr ME Cancer Pract; 1996; 4(1):35-9. PubMed ID: 8788769 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]